Protalix BioTherapeutics, Inc. (PLX) Dividend History

Protalix BioTherapeutics, Inc. is an Israeli biopharmaceutical company specializing in the development and commercialization of plant cell-based recombinant protein production technology. The company's technology platform aims to create cost-effective and scalable treatments for rare and ultra-rare orphan diseases. Protalix is known for its focus on enzyme replacement therapies and has developed products such as taliglucerase alfa for Gaucher disease.

Dividend History

Protalix BioTherapeutics, Inc. currently does not pay dividends

Company News

[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

The global Fabry disease treatment market is expected to grow from $2.76 billion in 2024 to $7.02 billion by 2034, at a CAGR of 9.8%. Key factors driving the market include FDA clearance of Fabry disease drugs and increased R&D investment.

GlobeNewswire Inc.
Pluxee to acquire Cobee, an innovative Spanish digital player in Employee Benefits

Pluxee to acquire Cobee, an innovative Spanish digital player in Employee Benefits

GlobeNewswire Inc.
Pluxee signe un accord pour l’acquisition de Cobee, un acteur digital espagnol innovant des avantages aux salariés

Pluxee signe un accord pour l’acquisition de Cobee, un acteur digital espagnol innovant des avantages aux salariés

GlobeNewswire Inc.
Pluxee firma un acuerdo para adquirir Cobee, empresa digital e innovadora de origen español especializada en beneficios para empleados

Pluxee firma un acuerdo para adquirir Cobee, empresa digital e innovadora de origen español especializada en beneficios para empleados

GlobeNewswire Inc.
Declaration of transactions in own shares n 2024/07

Regulated information

GlobeNewswire Inc.

Dividend data last updated 06/08/2025 01:48:34 UTC